In diabetics, use of GLP-1 agonist drugs or metformin was associated with considerably lower risk of cancer than use of insulin.
The followup period was 15 years. This was a retrospective cohort study.
(This result is not surprising, given insulin’s well-known growth promoting properties, which stimulate cancer cell division.)

